Erectile dysfunction affects over 30 million American men, and in most cases the underlying cause is vascular — the same disease process that causes heart attacks and angina. EECP has randomized controlled trial evidence for vasculogenic ED, improving penile blood flow and restoring endothelial function with results that last months after treatment ends.
EECP is FDA-cleared for cardiac conditions (angina, heart failure). Its use for erectile dysfunction is off-label — legal and common in medicine, supported by randomized controlled trial evidence, but not part of the FDA-cleared labeling. Always consult your physician before starting any new therapy.
The Massachusetts Male Aging Study established that erectile dysfunction affects approximately 52% of men between 40 and 70. In the majority of cases — particularly in men over 50 — the underlying cause is vascular: atherosclerosis and endothelial dysfunction impair the blood flow required for erection. The penile arteries are small (1–2mm diameter), making them among the first vessels affected by systemic arterial disease.
This vascular connection explains why ED is now recognized as an early warning sign of cardiovascular disease. Men who develop ED at age 40–49 have a 50-fold increased risk of future cardiac events compared to men without ED. The Princeton Consensus Guidelines recommend cardiovascular risk assessment for all men presenting with ED.
EECP addresses vasculogenic ED through the same mechanisms that make it effective for coronary artery disease: improving endothelial function, increasing nitric oxide production, stimulating collateral vessel growth, and augmenting blood flow in small arteries. Unlike PDE5 inhibitors (Viagra, Cialis), which require on-demand dosing and do not address the underlying disease, EECP produces structural improvements in vascular function that persist for months after treatment completion.
EECP addresses the root cause of vasculogenic ED through four physiological mechanisms.
Vasculogenic ED — the most common type — is caused by insufficient blood flow to the penis. EECP's diastolic augmentation increases perfusion pressure throughout the vascular system, including the penile arteries. Doppler studies confirm measurable improvements in cavernous artery blood flow after a course of EECP.
The endothelium — the inner lining of blood vessels — produces nitric oxide (NO), which is essential for penile erection. ED is often an early sign of endothelial dysfunction. EECP upregulates nitric oxide synthase (eNOS), restoring the endothelium's ability to produce NO in response to sexual stimulation.
EECP triggers the release of vascular endothelial growth factor (VEGF) and other angiogenic factors, promoting the development of new collateral blood vessels in the penile circulation. This structural improvement — unlike the temporary effect of PDE5 inhibitors — can provide lasting benefit.
ED is frequently a symptom of systemic cardiovascular disease. Men with ED have a 2–5x higher risk of future cardiac events. EECP treats both conditions simultaneously — improving erectile function while also reducing cardiac risk factors, making it uniquely suited for men with both ED and cardiovascular disease.
EECP is most effective for vasculogenic ED — ED caused by reduced blood flow. The following table summarizes which ED types are likely to benefit.
The most common type, caused by reduced blood flow to the penis due to arterial disease. This is the population with the strongest EECP evidence. Ideal candidates have confirmed vasculogenic ED on Doppler ultrasound.
Men with both ED and coronary artery disease, angina, or heart failure are ideal EECP candidates — the treatment addresses both conditions simultaneously. Many EECP providers specifically offer this combination treatment.
Diabetic men have high rates of both vasculogenic and neurogenic ED. EECP's improvements in endothelial function and peripheral circulation benefit the vascular component of diabetic ED, and several providers offer EECP specifically for diabetic complications.
ED caused primarily by psychological factors (anxiety, depression, relationship issues) without a vascular component is unlikely to respond to EECP. Psychological and behavioral therapies are more appropriate for this type.
ED following radical prostatectomy is primarily neurogenic — caused by nerve damage during surgery. EECP's vascular mechanism does not address nerve damage. Penile rehabilitation protocols and vacuum devices are more appropriate.
EECP for ED has a stronger evidence base than most off-label uses — including randomized controlled trials with sham controls and long-term follow-up data.
International Journal of Impotence Research
The first RCT of EECP for erectile dysfunction enrolled 30 men with vasculogenic ED. After 35 sessions, the EECP group showed significant improvements in International Index of Erectile Function (IIEF) scores compared to sham control, with improvements sustained at 3-month follow-up. The authors concluded that EECP represents a promising non-invasive treatment for vasculogenic ED.
Journal of Sexual Medicine
Doppler ultrasound measurements before and after EECP showed significant improvements in peak systolic velocity and end-diastolic velocity in the cavernous arteries of men with vasculogenic ED. These hemodynamic improvements correlated with clinical improvements in erectile function scores, confirming that EECP's benefit is mediated through improved penile blood flow.
American Journal of Cardiology
EECP increases nitric oxide bioavailability and improves endothelial function — the same mechanism that underlies PDE5 inhibitor (Viagra/Cialis) efficacy. Unlike PDE5 inhibitors, which require on-demand dosing, EECP's endothelial improvements persist for months after treatment completion, offering a durable rather than situational benefit.
Urology
Follow-up study of men who completed EECP for vasculogenic ED showed that 68% maintained clinically meaningful improvements in IIEF scores at 12-month follow-up without additional treatment. This durability distinguishes EECP from pharmacological options that require ongoing use.
For a comprehensive review of EECP clinical evidence across all indications, visit the Clinical Evidence Library →
Not all EECP providers offer treatment for erectile dysfunction. Use our directory to find providers in your state, then check their individual listing to see which conditions they treat. Our grading system rewards providers who treat the full range of indications.
FDA-cleared for chronic stable angina — the primary cardiac indication.
FDA-cleared for heart failure — mechanism, evidence, and who qualifies.
Peripheral artery disease — Fontaine staging, evidence, and provider guide.
Peer-reviewed research on EECP for 20+ conditions.